Immunotherapies Against HIV
The Human Immunodeficiency Virus (HIV) is the causal agent of the spectrum of disorders known as Acquired Immune Deficiency Syndrome (AIDS). For decades, those infected have found relief from anti-retroviral therapies that suppress viral numbers. Howeve
Talking Biotech with Dr. Kevin Folta · Kevin M. Folta
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The Human Immunodeficiency Virus (HIV) is the causal agent of the spectrum of disorders known as Acquired Immune Deficiency Syndrome (AIDS). For decades, those infected have found relief from anti-retroviral therapies that suppress viral numbers. However, the treatments are difficult, require strict compliance and are not 100% efficacious. New therapies have been developed that target the virus using Chimeric Antigen Receptor engineered T cells. These immune cells have been armed with genetically engineered receptors and localization signals that home in on a target, like HIV. Dr. Pamela Skinner is a Professor at the University of Minnesota. Her group collaborates with other leading labs to develop CAR-T cell based therapies for HIV, and she is optimistic about the success of these new approaches.
Dr. Skinner’s Website is here.
# COLABRA
Talking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/
# TALKING BIOTECH
Twitter: https://twitter.com/talkingbiotech
Website: https://www.colabra.app/podcasts/talking-biotech/
Instagram: https://www.instagram.com/colabrahq
The Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.